DXCM vs PODD
DXCM: Dexcom is a leading medical technology company specializing in continuous glucose monitoring (CGM) systems that help people with diabetes manage their condition with real-time data. PODD: Insulet provides the Omnipod system, a revolutionary tubeless, wearable insulin pump platform that simplifies diabetes management through automated insulin delivery.
Side-by-side fundamentals
| Metric | DXCM | PODD | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $84.41 | $134.47 | |
| Market cap | $31.9B | $9.3B | |
| P/E as of 2026-10-08 | 33.60 | 25.16 | PODD lower |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | 0.92 | n/a | |
| Net margin FY2025, SEC XBRL | +17.9% | +9.1% | DXCM higher |
| Gross margin FY2025, SEC XBRL | +60.1% | +71.6% | PODD higher |
| Operating margin FY2025, SEC XBRL | +19.6% | +17.5% | DXCM higher |
| ROE FY2025, SEC XBRL | +30.5% | +16.3% | DXCM higher |
| ROA FY2025, SEC XBRL | +13.2% | +7.7% | DXCM higher |
| Debt / equity as of 2026-09-03 | 0.49 | 0.63 | DXCM lower |
| Revenue growth (YoY) as of 2026-09-03 | +15.5% | +29.4% | PODD higher |
| Revenue CAGR (3y) SEC XBRL | +17.0% | +27.5% | PODD higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.89 | 0.64 | |
| 1-year return as of 2026-10-08 close | +24.5% | -57.4% | DXCM higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.